Urdafalk indications
Hypertension:
Lisinopril is indicated for the treatment of hypertension. It may be used alone as initial therapy or concomitantly with other classes of antihypertensive agents.
Heart Failure
lisinopril is indicated as adjunctive therapy in the management of heart failure in patients who are not responding adequately to diuretics and digitalis.
Acute Myocardial Infarction
Lisinopril is indicated for the treatment of hemodynamically stable patients within 24 hours of acute myocardial infarction, to improve survival. Patients should receive, as appropriate, the standard recommended treatments such as thrombolytics, aspirin and beta blockers.
Uses of Urdafalk in details
Ursodiol is a bile acid used to dissolve gallstones in patients who do not want surgery or cannot have surgery to remove gallstones. Ursodiol is also used to prevent the formation of gallstones in overweight patients who are undergoing rapid weight loss.
Urdafalk description
Urdafalk is a bile acid which is physiologically synthesized in the human liver and is also formed by bacteria in the large intestine. It is present in human bile making up 1.4-4% of the biliary bile acids. Urdafalk is an epimer of chenodeoxycholic acid; it differs from this bile acid only in the configuration of the hydroxyl group in the C7-position.
Urdafalk dosage
Capsule: Cholestatic Liver Disease and Dissolution of Cholesterol Gallstones: Approximately 10 mg/kg body weight/day equivalent to: Up to 60 kg: 2 capsules; up to 80 kg: 3 capsules; up to 100 kg: 4 capsules; >100 kg: 5 capsules.
Treatment of Biliary Reflux Gastritis: 1 capsule daily.
Symptomatic Treatment of Primary Biliary Cirrhosis: The daily dose depends on the body weight of the patient and lies between 2 and 6 capsules (approximately 10-15 mg/kg body weight).
The following method of taking of the capsules is recommended: See table 1.
Film-Coated Tablet: There are no age restrictions on the use of Urdafalk film-coated tablet. For patients weighing <47 kg or patients who are unable to swallow Urdafalk film-coated tablet 500 mg, Urdafalk capsules are available.
The following daily dose is recommended for the various
Indications: Dissolution of Cholesterol Gallstones: Approximately Urdafalk 10 mg/kg body weight, equivalent to: Up to 60 kg: 1 film-coated tablet, 61-80 kg: 1½ film-coated tablet, 81-100 kg: 2 film-coated tablet, >100 kg: 2½ film-coated tablet.
The film-coated tablets should be swallowed whole with some liquid in the evening at bedtime. They must be taken regularly.
The time required for the dissolution of gallstones is generally 6-24 months. If there is no reduction in the size of the gallstones after 12 months, the therapy should not be continued.
The success of the treatment should be checked by means of ultrasound or x-ray examination every 6 months. At the follow-up examinations, a check should be made to see whether calcification of the stones has occurred in the meantime. Should this be the case, the treatment must be ended.
Symptomatic Treatment of Primary Biliary Cirrhosis (PBC): The daily dose depends on body weight and ranges from 1½ to 3½ film-coated tablets (Urdafalk 14±2 mg/kg of body weight). For the first 3 months of treatment, Urdafalk film-coated tablet should be taken divided over the day. When the liver function parameters improve, the daily dose may be taken once daily in the evening.
The film-coated tablets should be swallowed whole with some liquid. They must be taken regularly.
The use of Urdafalk film-coated tablet in primary biliary cirrhosis may be continued indefinitely.
In patients with primary biliary cirrhosis, in rare cases, the clinical symptoms may worsen at the beginning of treatment eg, the itching may increase. In this event, therapy should first be continued with ½ an Urdafalk film-coated tablet 500 mg or 1 Urdafalk capsule (containing Urdafalk 250 mg) daily and the dose then gradually increased (weekly increase of the daily dose by ½ a film-coated tablet or 1 Urdafalk capsule) until the dose indicated in the respective dosage regimen is reached again.
Urdafalk interactions
Urdafalk should not be administered concomitantly with cholestyramine, colestipol or antacids containing aluminum hydroxide and/or smectite (aluminum oxide), because these preparations bind Urdafalk in the intestine and thereby inhibits its absorption and efficacy. Should the use of a preparation containing one of these active ingredients concomitantly be necessary, it must be taken at least 2 hrs before or after Urdafalk.
Urdafalk can increase the absorption of ciclosporin from the intestine. In patients receiving ciclosporin treatment, blood concentrations of this substance should therefore be checked by physician and the ciclosporin dose adjusted if necessary.
In isolated cases, Urdafalk can reduce the absorption of ciprofloxacin.
Film-Coated Tablet: Urdafalk has been shown to reduce peak plasma concentrations (Cmax) and area under the curve (AUC) of the calcium antagonist nitrendipine.
An interaction with a reduction of the therapeutic effects of dapsone was also reported.
These observations, together with in vitro findings could indicate a potential for Urdafalk to induce cytochrome P450 (CYP450) 3A enzymes. Controlled clinical studies have shown, however, that Urdafalk does not have a relevant inductive effect on CYP450 3A enzymes.
Estrogenic hormones and blood cholesterol-lowering agents eg, clofibrate may increase biliary lithiasis, which is a counter-effect to Urdafalk used for dissolution of gallstones.
Urdafalk side effects
Urdafalk is generally well-tolerated. It may cause nausea, vomiting and other gastrointestinal disturbances but diarrhea is reported to occur less frequently than with chenodeoxycholic acid. Increased liver enzyme values are also less likely. Pruritus may occur. Other adverse effect reactions are headache, insomnia, bronchitis, upper respiratory tract infection, arthralgia, myalgia.
Urdafalk contraindications
Hypersensitivity to Urdafalk or to any of the excipients of Urdafalk.
Patients with complete obstruction of biliary tract (choleretic actions may aggravate the symptoms), fulminant hepatitis, radiopaque calcifying cholelith, nonfunctioning cholecyst or acute cholecystitis, renal disease, gastric ulcers (acute gastroduodenal ulcers), colitis or enteritis eg, Crohn's disease.
Use in pregnancy: Do not administer to pregnant women or women suspected of being pregnant.
Use in children: Do not administer to pediatric patients.
Active ingredient matches for Urdafalk:
Ursodeoxycholic Acid in Indonesia.
| Unit description / dosage (Manufacturer) | Price, USD |
| Urdafalk 250 mg x 30's | $ 26.60 |
List of Urdafalk substitutes (brand and generic names): | |
| Urchil Forte (India) | |
| Urchil Forte 300mg Tablet (Sioux (Aamorb Pharmaceuticals Pvt Ltd) | $ 0.22 |
| Urdahex (Indonesia) | |
| Urdahex 250 mg x 3 x 10's (Kalbe Farma) | $ 27.78 |
| Urdecole (Argentina) | |
| Urdenacin (Japan) | |
| Urdes (Italy) | |
| Urdeston (Japan) | |
| Urdex (Japan) | |
| Urdiogem (India) | |
| Urdiogem 300 mg Tablet (Alembic Chemical Works Co Ltd) | $ 0.18 |
| URDIOGEM 150 MG TABLET 1 strip / 10 tablets each (Alembic Chemical Works Co Ltd) | $ 1.34 |
| URDIOGEM 300 MG TABLET 1 strip / 10 tablets each (Alembic Chemical Works Co Ltd) | $ 2.42 |
| URDIOGEM tab 150 mg x 10's (Alembic Chemical Works Co Ltd) | $ 1.11 |
| URDIOGEM tab 300 mg x 10's (Alembic Chemical Works Co Ltd) | $ 2.01 |
| Urdiogem 150mg Tablet (Alembic Chemical Works Co Ltd) | $ 0.15 |
| Urdiogem 300mg Tablet (Alembic Chemical Works Co Ltd) | $ 0.29 |
| URDOHEP | |
| URDOHEP 150 MG TABLET 1 strip / 10 tablets each (Macleods (Oxalis)) | $ 1.17 |
| URDOHEP 300 MG TABLET 1 strip / 10 tablets each (Macleods (Oxalis)) | $ 2.57 |
| URDOHEP tab 150 mg x 10's (Macleods (Oxalis)) | $ 1.28 |
| URDOHEP tab 300 mg x 10's (Macleods (Oxalis)) | $ 2.33 |
| Urdohep 150mg Tablet (Macleods (Oxalis)) | $ 0.14 |
| Urdohep 300mg Tablet (Macleods (Oxalis)) | $ 0.27 |
| Urdoxa | |
| Capsule; Oral; Ursodeoxycholic Acid 250 mg | |
| URICURE | |
| URICURE 150MG TABLET 1 strip / 10 tablets each (Emcure Pharmaceuticals Ltd) | $ 1.30 |
| URICURE 300MG TABLET 1 strip / 10 tablets each (Emcure Pharmaceuticals Ltd) | $ 2.45 |
| Uricure 300mg Tablet (Emcure Pharmaceuticals Ltd) | $ 0.25 |
| URIJON (India) | |
| URIJON 300 MG TABLET 1 strip / 10 tablets each (D.R John's Lab Pharma) | $ 2.89 |
| URIJON tab 300 mg x 10's (D.R John's Lab Pharma) | $ 2.89 |
| Urijon 300mg Tablet (D.R John's Lab Pharma) | $ 0.31 |
| Urlyx (Philippines) | |
| Urlyx cap 250 mg 100's (Lloyd) | |
| URMED | |
| URMED-300 TABLET 1 strip / 10 tablets each (Medsea Healthcare Pvt Ltd) | $ 2.82 |
| Urmed 300mg Tablet (Medsea Healthcare Pvt Ltd) | $ 0.45 |
| Urmed 450mg Tablet SR (Medsea Healthcare Pvt Ltd) | $ 0.60 |
| URODELL (India) | |
| URODELL tab 300 mg x 10's (Aero-Chem) | |
| UROLIV (India) | |
| UROLIV tab 300 mg x 10's (Shinto Biotec) | $ 5.90 |
| Urose (Taiwan) | |
| Urose 300 mg | |
| Uroso (Taiwan) | |
| Uroso 100 mg | |
| Urosodil | |
| Urosodil 250 mg Capsule (German Remedies (Zydus Cadila Healthcare Ltd.)) | $ 0.18 |
| Urosofalk (Portugal) | |
| UROSTONE | |
| UROSTONE 300MG TABLET 1 strip / 10 tablets each (Oasis Laboratories Pvt Ltd) | $ 3.37 |
| URS | |
| URS 300 mg Tablet (Synokem Pharmaceuticals Ltd) | $ 0.20 |
| URS 150 mg Tablet (Synokem Pharmaceuticals Ltd) | $ 0.11 |
| URS 150MG TABLET 1 strip / 10 tablets each (Synokem Pharmaceuticals Ltd) | $ 2.37 |
| URS 150MG TABLET 1 strip / 4 tablets each (Synokem Pharmaceuticals Ltd) | $ 0.42 |
See 835 substitutes for Urdafalk | |
References
- DailyMed. "URSODIOL: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- PubChem. "URSODEOXYCHOLIC ACID". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
- DrugBank. "URSODEOXYCHOLIC ACID". http://www.drugbank.ca/drugs/DB01586 (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Urdafalk are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Urdafalk. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
1 consumer reported useful
Was the Urdafalk drug useful in terms of decreasing the symptom or the disease?According to the reports released by ndrugs.com website users, the below mentioned percentages of users say the drug is useful / not useful to them in decreasing their symptoms/disease. The usefulness of the drug depends on many factors, like severity of the disease, perception of symptom, or disease by the patient, brand name used [matters only to a certain extent], other associated conditions of the patient. If the drug is not effective or useful in your case, you need to meet the doctor to get re-evaluated about your symptoms/disease, and he will prescribe an alternative drug.
| Users | % | ||
|---|---|---|---|
| Useful | 1 | 100.0% | |
Consumer reported price estimates
No survey data has been collected yet1 consumer reported time for results
To what extent do I have to use Urdafalk before I begin to see changes in my health conditions?As part of the reports released by ndrugs.com website users, it takes 5 days and a few days before you notice an improvement in your health conditions.
Please note, it doesn't mean you will start to notice such health improvement in the same time frame as other users. There are many factors to consider, and we implore you to visit your doctor to know how long before you can see improvements in your health while taking Urdafalk. To get the time effectiveness of using Urdafalk drug by other patients, please click here.
| Users | % | ||
|---|---|---|---|
| 5 days | 1 | 100.0% | |
2 consumers reported age
| Users | % | ||
|---|---|---|---|
| 46-60 | 1 | 50.0% | |
| 16-29 | 1 | 50.0% | |
Consumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
